Hannover Medical School

This phase 4 trial tests whether empagliflozin, a diabetes drug, can safely slow kidney growth and preserve kidney function in 44 adults with rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). Participants take either empagliflozin or a placebo for 18 month…

This study tests whether a lung cancer screening program can work effectively in Germany. Over 12,000 current or former smokers aged 55-79 will be screened using two different risk-based methods to see which finds more cancers early. The goal is to integrate screening into existi…

This study looks at whether online psychotherapy, a physical activity program, or a combination of both can reduce fatigue in people with Post-COVID syndrome. 195 adults with fatigue will be assigned to one of three groups for 3 months of treatment. The goal is to find which appr…

This study looks at whether people with chronic hepatitis delta who have been on bulevirtide for at least 48 weeks and have very low virus levels can safely stop treatment. Researchers will monitor 20 participants for 48 weeks after stopping to find biological markers that predic…

This study uses artificial intelligence to analyze data from 5,000 people with autoimmune hepatitis. The goal is to create a computer model that can predict which patients will respond well to standard therapy within 6 to 12 months. By identifying these patterns early, doctors ma…

This observational study follows 11 patients with chronic hepatitis B and delta coinfection and liver cirrhosis who are already receiving the antiviral drug Bulevirtide. Researchers want to see if suppressing the virus reduces portal hypertension—a dangerous buildup of pressure i…